Parnassus Investments
Parnassus Endeavor Fund
Parnassus Endeavor Fund Bio-Rad Laboratories Inc stake
total: 118
Parnassus Endeavor Fund BIO trades
- Total transactions:
- 9
- New positions:
- 1
- Sold out:
- 1
- Added:
- 4
- Reduced:
- 3
- Held since:
- 2023 Q3
- Held for:
- 11 quarters
- Latest activity:
- 2026 Q2
According to 2026 Q2 report, Parnassus Endeavor Fund doesn't hold any Bio-Rad Laboratories Inc (BIO) shares. To date, the estimated cost basis is nearly $334.23 for "buy" trades and estimated average "sell" price is $283.44. Parnassus Endeavor Fund first purchased BIO in 2023 Q3, initially acquiring 220,791 shares. Since the initial investment in Bio-Rad Laboratories Inc (BIO), Parnassus Endeavor Fund has made 8 more transactions.
When did Parnassus Endeavor Fund sell Bio-Rad Laboratories Inc (BIO)?
Parnassus Endeavor Fund sold off the entire Bio-Rad Laboratories Inc (BIO) position in 2026 Q2.
When did Parnassus Endeavor Fund buy Bio-Rad Laboratories Inc (BIO)?
Parnassus Endeavor Fund first invested in Bio-Rad Laboratories Inc (BIO) in 2023 Q3 at the reported quarter-end price of $358.45 per share.
What's the cost basis of Parnassus Endeavor Fund's BIO stake?
The estimated cost basis for Bio-Rad Laboratories Inc (BIO) stake is around $334.23 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $334.23
- Weighted AVG sell price:
- $283.44
Parnassus Endeavor Fund's historical trades in Bio-Rad Laboratories Inc
9 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
0.00%
|
0
|
$278.75
|
|
-100% (-252,774)
|
-1.52%
|
|
2026 Q1
|
1.52%
|
252,774
|
$278.75
|
$70,460,752
|
+0.64% (+1,598)
|
+0.01%
|
|
2025 Q4
|
1.60%
|
251,176
|
$302.99
|
$76,103,816
|
-20.11% (-63,222)
|
-0.41%
|
|
2025 Q3
|
1.87%
|
314,398
|
$280.39
|
$88,154,055
|
-0.62% (-1,963)
|
-0.01%
|
|
2025 Q2
|
1.68%
|
316,361
|
$241.32
|
$76,344,237
|
-0.34% (-1,075)
|
-0.01%
|
|
2025 Q1
|
1.73%
|
317,436
|
$243.56
|
$77,314,712
|
+2.16% (+6,704)
|
+0.04%
|
|
2024 Q2
|
1.73%
|
310,732
|
$273.11
|
$84,864,017
|
+30.67% (+72,942)
|
+0.41%
|
|
2023 Q4
|
1.56%
|
237,790
|
$322.89
|
$76,780,013
|
+7.70% (+16,999)
|
+0.11%
|
|
2023 Q3
|
1.74%
|
220,791
|
$358.45
|
$79,142,534
|
new
|
+1.74%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.